AC Immune Presents New Phase 1 Data Indicating Higher Uptake of TDP-43 PET Tracer ACI-19626 in Patients with ALS
AC Immune presented new Phase 1 data for its TDP-43 PET tracer ACI-19626, showing significantly higher uptake in the brains of ALS patients compared to healthy controls. The results, presented at the 2026 TDP43 Summit, confirm the tracer’s ability to detect TDP-43 pathology in key brain regions like the brain stem and precentral gyrus, consistent with post-mortem studies.
Key figures
- Drug Name
- ACI-19626
- Phase Of Trial
- Phase 1
- Potential milestone payments
- > $4.5 billion
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.